TNXP 8-K 2026-11-09

Tonix Pharmaceuticals Holding Corp. (TNXP) 8-K dated 2026-11-09 — accession 0001493152-26-050621.

Tonix Pharmaceuticals Holding Corp. (TNXP) is a biotechnology company listed on NASDAQ.

TNXP: Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operat…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported TNXP revenue for 2025-12-31 was $13.1M. Net income was -$124.0M. Revenue was up 29.8% from 2024-12-31 to 2025-12-31. TNXP currently screens at market cap $194.5M.

Not investment advice. The TNXP SEC hub lists recent forms. The stock page is the research view.